Article thumbnail

The Molecular Chaperone α-Crystallin as an Excipient in an Insulin Formulation

By Tue Rasmussen, Ruedeeporn Tantipolphan, Marco van de Weert and Wim Jiskoot
Topics: Research Paper
Publisher: Springer US
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. Plos Biol.
  2. (2004). Ageing and vision: structure, stability and function of lens crystallins. Prog Biophys Mol Biol.
  3. (1996). All about albumin, Biochemistry, genetics, and medical applications.
  4. (1992). Alpha-crystallin can function as a molecular chaperone.
  5. Chaperone-like activity and hydrophobicity of alpha-crystallin.
  6. (2005). Chaperone-like features of bovine serum albumin: a comparison with alphacrystallin. Cell Mol Life Sci.
  7. (1997). Conformational and functional differences between recombinant human lens alpha A- and alpha B-crystallin.
  8. (2009). Crystallin proteins and amyloid fibrils. Cell Mol Life Sci.
  9. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism.
  10. (2006). Effects of protein aggregates: an immunologic perspective.
  11. (2004). Excipients for use in lyophilized pharmaceutical peptide, protein, and other bioproducts.
  12. (2003). Exp Eye Res.
  13. (2008). Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res.
  14. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/“Ockham’s razor” model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth.
  15. (2009). Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci.
  16. (2007). Formulation development for hydrophobic therapeutic proteins. Pharm Dev Tech.
  17. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species.
  18. (1999). Human 60-kDa heat-shock protein: a danger signal to the innate immune system.
  19. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals.
  20. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
  21. (1998). Intermolecular exchange and stabilization of recombinant human alpha A- and alpha B-crystallin.
  22. (1986). Kinetics of sickle hemoglobin polymerization. III. Nucleation rates determined from stochastic fluctuations in polymerization progress curves.
  23. (1991). Lens proteins and their genes. Prog Nucleic Acid Res Mol Biol.
  24. Lyophilization and development of solid protein pharmaceuticals.
  25. Mechanism of chaperone function in small heat shock proteins. Two-mode binding of the excited states of T4 lysozyme mutants by alphaAcrystallin.
  26. (1992). Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol Bioeng.
  27. (2004). Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res.
  28. (1981). Molecular and cellular biology of the eye lens.
  29. Monitoring the prevention of amyloid fibril formation by alphacrystallin.
  30. Near-ultraviolet tyrosyl circulardichroism of pig insulin monomers, dimers, and hexamers— dipole-dipole coupling calculations in monopole approximation.
  31. (2000). Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immun.
  32. not stirred: mechanical stress testing of an IgG1 antibody.
  33. Partially folded intermediates in insulin fibrillation.
  34. (2008). Particulate contamination: sub-visible particles. European directorate for the quality of medicine
  35. Protein aggregation: pathways, induction factors and analysis.
  36. (2005). Protein drug stability: a formulation challenge. Nat Rev Drug Discovery.
  37. Secondary nucleation and accessible surface in insulin amyloid fibril formation.
  38. (1998). Structural perturbation of alpha-crystallin and its chaperone-like activity.
  39. Structure and mechanism of protein stability sensors: chaperone activity of small heat shock proteins.
  40. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res.
  41. (1995). Temperature-induced exposure of hydrophobic surfaces and its effect on the chaperone activity of alpha-crystallin.
  42. (1998). The chaperone-like alpha-crystallin forms a complex only with the aggregation-prone molten globule state of alpha-lactalbumin. Biochem Biophys Res Commun.
  43. The chaperone-like protein alpha-crystallin dissociates insulin dimers and hexamers.
  44. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor.
  45. Thermal dissociation and unfolding of insulin.
  46. (1975). Thermodynamics of the polymerization of proteins.
  47. (1981). Timasheff SN. The stabilization of proteins by sucrose.